Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mixing and matching drugs: what makes sense?

Clinics in liver disease - 1 Aug 2011

Welzel Tania M, Zeuzem Stefan

Abstract excerpt

The introduction and ongoing development of directly acting antiviral agents (DAAs) and drugs targeting host cell structures will change the management of patients with chronic hepatitis C virus (HCV) infection. The concomitant use of the protease inhibitors telaprevir or boceprevir with the standard of care, a combination of pegylated interferon (PegIFN) and ribavirin, will represent the new standard for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Viral Nonstructural Proteins
Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Protease Inhibitors

Share to Ribavirin

Source

Identifiers

PMID: 21867943
DOI: 10.1016/j.cld.2011.05.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mixing and matching drugs: what makes sense?PMID 21867943Read ↗

[Treatment of chronic hepatitis viral C: new associations].Semantic proximity Read ↗

Into the light: strategies for battling hepatitis C.Semantic proximity Read ↗

Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.Semantic proximity Read ↗

Direct-acting Antivirals for HIV/HCV Co-infected Individuals: As Good as it Gets?Semantic proximity Read ↗

Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues.Semantic proximity Read ↗

Drug development: Mix and match.Semantic proximity Read ↗

Telaprevir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry.Semantic proximity Read ↗

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.Semantic proximity Read ↗

Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.Semantic proximity Read ↗

Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.Semantic proximity Read ↗

Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.